HQK-1001

DRUG5 trials

Sponsors

HemaQuest Pharmaceuticals Inc.

Conditions

Beta ThalassemiaHealthyHemoglobin S DiseaseSickle Cell AnemiaSickle Cell DiseaseSickle Cell DisordersSickling Disorder Due to Hemoglobin S

Phase 1

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

CompletedNCT00717262

HemaQuest Pharmaceuticals Inc.Healthy

Start: 2008-05-31End: 2008-09-30Target: 41Updated: 2009-01-16

Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

CompletedNCT00790127

HemaQuest Pharmaceuticals Inc.Beta Thalassemia

Start: 2009-03-31End: 2010-05-31Updated: 2011-05-20

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

CompletedNCT00842088

HemaQuest Pharmaceuticals Inc.Sickle Cell Disease

Start: 2009-03-31Updated: 2011-08-01

Phase 2

A Study of HQK-1001 in Patients With Sickle Cell Disease

CompletedNCT01322269

HemaQuest Pharmaceuticals Inc.Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disease +2

Start: 2011-04-30Updated: 2013-06-19

Effects of HQK-1001 in Patients With Sickle Cell Disease

TerminatedNCT01601340

HemaQuest Pharmaceuticals Inc.Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disease +2

Start: 2012-07-31End: 2013-12-31Updated: 2015-03-18

Related Papers

5613423 TREATMENT OF ERYTHROID PRECURSOR CELLS FROM β-THALASSEMIC PATIENTS WITH ISOXAZOLE DERIVATIVES: POTENT INDUCTION OF FETAL HEMOGLOBIN

HemaSphere2023-04-01